09:00 – 09:05
09:05 – 09:15
09:15– 09:45
Industry Leader Lecture
Pioneering company creation model and opportunities in APAC
09:45 – 10:15
PROGRAM
2024 Innovation Forum Agenda
2024 Innovation Forum Agenda
Date July 24-26, 2024
Venue July 24 Room 701AB & 701C, 7F, TaiNEX2
July 25-26 Room 401, 4F, TaiNEX1
Day 1 - Wednesday, July 24
Day 2 - Thursday, July 25
Day 3 - Friday, July 26
09:00 – 10:15
Session 1 (Plenary) – Global Biotech Development
TBD
Industry Leader Lecture
10:20 – 12:05
Session 2 (Plenary) – Global Biotech Development
Welcome to the conference component of BIO Asia–Taiwan 2024, beginning with two Plenary
Sessions on Global Biotech Development. Hear from representatives of the Biotechnology
Innovation Organization (BIO), discussing biopharma policy and regulatory changes; and US-
based Flagship Pioneering, examining innovative company creation models as well as
collaboration opportunities within Asia. And don’t miss the Tang Prize Lecture; an Exploration of
Biological Diversity, by Feng Zhang, Tang Prize Laureate. In Session 2 we'll dive right into AI in
healthcare, funding and investment strategies, and emerging trends in both the pharmaceutical
industry and in the broader healthcare spaces. Join our esteemed lineup of speakers from Asia
and around the world as they offer their insights on navigating the global biotech landscape.
10:20 – 10:40
Global Biotech Top Trends --- From a US Silicon Valley VC Prospective
10:40 – 11:00
Bioconvergence: how the intersection of biology and technology can advance human health
Paru Deshpande, Vice President R&D, Health Technologies, Imec vzw
11:00 – 11:20
Emerging Trends in the Global Health Industry
Zubin J. Daruwalla, M. D., PwC Singapore and Asia Pacific Health Industries Leader, PwC Singapore
11:20 – 11:40
Global trends and Future Opportunities in Pharma
11:40 – 12:00
Evidence Based Cell and Gene Therapies: Global development for local benefit
12:00 – 12:05
Closing Remarks
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
12:30 – 14:00
Session 3 (Plenary) – Through International Alignment for a Healthier Taiwan
TBD
12:30 – 12:40
12:40 – 12:55
Empowering Taiwanese Biomedical Startups through International Collaboration
12:55 – 13:10
Establish an Interdisciplinary Collaboration Platform for Biomedical Innovations in Taiwan
13:10 – 13:25
Toward Enhancing Japan's Drug Discovery Capabilities
Toshihiko Takeda, Special Advisor, National Healthcare Policy Secretariat, Cabinet Secretariat, Government of Japan.
13:25 – 13:55
Panel Discussion
Moderator:
Panelists:
- Toshihiko Takeda, Special Advisor, National Healthcare Policy Secretariat, Cabinet Secretariat, Government of Japan.
- Lily Wong, Partner, PwC Taiwan
- Eric Y. Chuang, Vice President, General Director, Biomedical Technology and Device Research Laboratories, ITRI
- Frances Milnes, Country President, Novartis (Taiwan) Co., Ltd.
13:55 – 14:00
14:10 – 15:40
Session 4 – ADC Drug Development and Manufacturing Trends Challenges and Solutions
Antibody-Drug Conjugate (ADC) drugs, while becoming more and more mainstream, still
provide significant manufacturing challenges. This session will examine the latest ADC
development and manufacturing trends such as biomarker-incorporated ADCs, novel payloads,
site-specific conjugation, and novel combination therapies; identify challenges including payload
stability and manufacturing scalability; and consider solutions such as better process
optimization and improved conjugation technologies. Don't miss this deep dive into the world of
ADCs, led by some of the world's leading experts in this field.
provide significant manufacturing challenges. This session will examine the latest ADC
development and manufacturing trends such as biomarker-incorporated ADCs, novel payloads,
site-specific conjugation, and novel combination therapies; identify challenges including payload
stability and manufacturing scalability; and consider solutions such as better process
optimization and improved conjugation technologies. Don't miss this deep dive into the world of
ADCs, led by some of the world's leading experts in this field.
14:10 – 14:15
Opening Remarks
Lee-Cheng Liu, Founder, Chairman & President, EirGenix, Inc.
14:15 – 14:35
Challenges and Opportunities of ADC Drug Development: Regulatory Considerations
14:35 – 14:55
Strategies for Widening the Therapeutic Window
14:55 – 15:15
Nab2-ADC: Revolutionizing Antibody-Drug Conjugates with Enhanced Targeting and Safety
Gui-Dong Zhu, CEO, SparX Biopharmaceutical Corp.15:15– 15:40
16:00 – 17:30
Session 5 – Frontier of Gene and Cell Therapies
This session will explore the latest advancements, challenges, and future developments in the
field of gene and cell therapies. Bringing together leading experts, researchers, and clinicians,
we'll provide a comprehensive overview of cutting-edge technologies, such as CRISPR gene
editing, CRT-T and stem cell therapy. We'll highlight current gene and cell therapy applications
as well as the new treatments on the horizon. We'll uncover both drivers and bottlenecks to
progress in this exciting discipline, including challenges from a regulatory, manufacturing, and
ethical perspective. Attendees can expect an invigorating discussion around this rapidly-
evolving topic.
field of gene and cell therapies. Bringing together leading experts, researchers, and clinicians,
we'll provide a comprehensive overview of cutting-edge technologies, such as CRISPR gene
editing, CRT-T and stem cell therapy. We'll highlight current gene and cell therapy applications
as well as the new treatments on the horizon. We'll uncover both drivers and bottlenecks to
progress in this exciting discipline, including challenges from a regulatory, manufacturing, and
ethical perspective. Attendees can expect an invigorating discussion around this rapidly-
evolving topic.
16:00 – 16:03
16:03 – 16:20
Overview of Landscape for Cell and Gene Therapies; An update
16:20 – 16:40
Driving the next generation of innovative and affordable cell therapies across indications
Alex Shih-Min Huang,VP & Head of Cell Therapy, BeiGene, BeiGene (Taiwan) Limited
16:40 – 16:55
Early Engagement Strategies to Cell and Gene Therapies Up for Success
16:55 – 17:10
Integration of MSC Value Chain with Enabling Manufacturing Platforms
David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)
17:10 – 17:25
Investors viewpoint on cell and gene therapy
17:25 – 17:30
Closing Remarks
09:00 – 10:30
Session 6 – mRNA and New Therapeutic Modalities
This session delves into the transformative potential of mRNA technology in modern
therapeutics. From the pioneering application of mRNA in COVID-19 vaccines, our expert
speakers will highlight advancements in mRNA therapeutics beyond vaccines, including as
personalized cancer treatments, where mRNA can direct the immune system to target and
destroy cancer cells. Additionally, we'll cover the development of mRNA-based therapies for
genetic disorders, such as cystic fibrosis, where mRNA can be used to produce functional
proteins. The latest research on mRNA delivery systems, stability, and manufacturing will also
be covered, addressing the key challenges and future prospects of this promising technology.
Join us to learn how mRNA is revolutionizing the landscape of therapeutic modalities and
paving the way for innovative treatments.
therapeutics. From the pioneering application of mRNA in COVID-19 vaccines, our expert
speakers will highlight advancements in mRNA therapeutics beyond vaccines, including as
personalized cancer treatments, where mRNA can direct the immune system to target and
destroy cancer cells. Additionally, we'll cover the development of mRNA-based therapies for
genetic disorders, such as cystic fibrosis, where mRNA can be used to produce functional
proteins. The latest research on mRNA delivery systems, stability, and manufacturing will also
be covered, addressing the key challenges and future prospects of this promising technology.
Join us to learn how mRNA is revolutionizing the landscape of therapeutic modalities and
paving the way for innovative treatments.
09:00 – 09:05
09:05 – 09:25
New Therapeutic Modalities for Treatment of Human Diseases
Yusuke Nakamura, President, National Institutes of Biomedical Innovation, Health and Nutrition
09:25 – 09:45
Updates for Gene Therapies - an industry perspective
09:45 – 10:05
The mRNA Equation: Balancing Promise and Practical Constraints
10:05 – 10:25
CMC Strategy for mRNA-LNP Vaccines and Therapeutics
Kelvin Chan, Director, Commercial Strategy & Business Development, Kudo Biotechnology, Inc.
10:25 – 10:30
10:35 – 12:15
Session 7 – Taiwan BIO Awards-Successful Stories
TBD
10:35–12:15
Sharing the Experience of Biotech Success
2024 Taiwan BIO Awards Winners:
- Outstanding Company of the Year
Lotus Pharmaceutical Co., Ltd. (美時化學製藥股份有限公司)
Valerie Lau, APAC Chief Commercial Officer
PharmaEssentia Corporation (藥華醫藥股份有限公司)
Albert Qin, Chief Medical Officer
BONRAYBIO CO., LTD. (邦睿生技股份有限公司)
Kevin Chuang, Sales V.P.
- Emerging Company of the Year
Pharmosa Biopharm Inc. (國邑藥品科技股份有限公司)
Pei / Kan, President & Cofounder
TSH Biopharm (東生華製藥股份有限公司)
Chuan-Hsu, Chen, Senior Marketing Director
Steminent Biotherapeutics Inc. (仲恩生醫科技股份有限公司)
Wang Lin-Mei, Chairman and CEO
Onyx Healthcare Inc. (醫揚科技股份有限公司)
John Chuang, President
BenQ Dialysis Technology Corp. (明基透析科技股份有限公司)
Spark Huang, Chairman
- Startup of the Year
Acepodia, Inc. (英屬開曼群島商育世博股份有限公司)
Sonny Hsiao, CEO & CSO
ImmunAdd Inc. (優億股份有限公司)
Pi-Hui Liang, CEO
Sunhawk Vision Biotech, Inc. (視航生物醫學股份有限公司)
Suh-Hang Hank Juo, President
Elixiron Immunotherapeutics Inc. (安立璽榮生醫股份有限公司)
Hung-Kai Chen, Chairman and Chief Executive Officer
BioGend Therapeutics Co., Ltd. (博晟生醫股份有限公司)
Lee, Po-Wei, Assistant Manager
BRAXX BIOTECH CO., LTD. (貝克生醫股份有限公司)
Vic Chang, CEO
Protect Biotech Inc. (寶泰生醫股份有限公司)
Pearl Fong, Chief R&D Officer
- Innovation of the Year
A Novel Ophthalmic Suspension of Clobetasol Propionate derived from APNT Nanoparticle Formulation Technology, USFDA-approved for the Treatment of Inflammation and Pain Following Ocular Surgery (APP13007: 以APNT奈米微粒製劑技術開發並於美國獲准上市之用於治療眼科術後發炎疼痛之丙酸氯倍他索滴眼懸液)
Erick Co, President & CEO, Formosa Pharmaceuticals, Inc.
Influenza Antiviral TG-1000 (流感抗病毒新藥TG-1000)
Li-Wen Chang, Vice President of Clinical Development, TaiGen Biotechnology
Stress EEG Assessment System (憂可視腦波壓力評估系統)
Tina Chang, Executive Assistant to GM, HippoScreen Neurotech Corporation
12:25-13:55
Session 8 –Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence
This will be a deep-dive into Chemistry, Manufacturing, and Controls (CMC) program design, an
essential element of every biologics development facility. We'll explore the latest advancements
and best practices in CMC to ensure the quality, efficacy, and safety of biologics products.
Emphasis will be on developments and practices emerging in Asia, where robust CMC
strategies have accelerated the growth of the region's biopharmaceutical sector. Case studies
will highlight successful CMC frameworks, showcasing advancements in manufacturing
technologies, regulatory harmonization, and cross-border collaborations. Join us to understand
how strategic CMC program design is driving biologics excellence and contributing to the global
success of the biopharmaceutical industry.
essential element of every biologics development facility. We'll explore the latest advancements
and best practices in CMC to ensure the quality, efficacy, and safety of biologics products.
Emphasis will be on developments and practices emerging in Asia, where robust CMC
strategies have accelerated the growth of the region's biopharmaceutical sector. Case studies
will highlight successful CMC frameworks, showcasing advancements in manufacturing
technologies, regulatory harmonization, and cross-border collaborations. Join us to understand
how strategic CMC program design is driving biologics excellence and contributing to the global
success of the biopharmaceutical industry.
12:25 – 12:30
12:30 – 12:50
Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development
Friedmund Bachmann, VP CMC, OncoOne Research & Development GmbH
12:50 – 13:10
Drug Bundle-Based ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads
13:10 – 13:30
Innovative CMC and Manufacturing Technologies for Next-Generation Bioconjugate Drug Development
13:30 – 13:50
Trends in CMC Design for Drug Products: What works and what doesn't
13:50 – 13:55
15:00–17:00
Session 9 – BIO Asia–Taiwan 2024 Opening & Award Ceremony
TBD
15:00-15:30
Admission
15:30-15:35
Introducing Honorable Guests
15:35-15:40
15:40-15:45
Opening Speech
15:45-15:55
15:55-16:20
Award Ceremony
• BIO Asia Awards
• 2024 Taiwan BIO Awards
16:20-16:30
Ribbon-cutting Ceremony
16:30
Adjourn
16:30-17:00
VIP Booth Tour
16:00 – 17:30
Session 10 – Translational Medicine, A Journey from Novelty to Commercial Success
This session explores the dynamic field of translational medicine, highlighting its journey
from innovative research to commercial triumph. Delve into the critical elements and processes
that bridge the gap between laboratory discoveries and marketable therapies. Case studies of
recent breakthroughs will illustrate how novel scientific insights are transformed into commercially
viable treatments, addressing unmet medical needs. Topics will include strategic partnerships,
regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety,
and an examination of successful funding mechanisms. Attendees will gain valuable knowledge
around navigating the complexities of translational medicine, and will learn how to effectively
translate cutting-edge research into life-changing therapies, driving innovation and improving
patient outcomes.
from innovative research to commercial triumph. Delve into the critical elements and processes
that bridge the gap between laboratory discoveries and marketable therapies. Case studies of
recent breakthroughs will illustrate how novel scientific insights are transformed into commercially
viable treatments, addressing unmet medical needs. Topics will include strategic partnerships,
regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety,
and an examination of successful funding mechanisms. Attendees will gain valuable knowledge
around navigating the complexities of translational medicine, and will learn how to effectively
translate cutting-edge research into life-changing therapies, driving innovation and improving
patient outcomes.
16:00 – 16:05
16:05 – 16:25
Understanding Protein Dynamics for Structure-based Drug Design: Design Stories of Crizotinib, Lorlatinib and Repotrectinib
Jingrong Jean Cui, President & CEO, BlossomHill Therapeutics, Inc.16:25 – 16:45
Bozitinib: from Bench to Bedside
Boyu Zhong, President, CSO, Tyligand Bioscience Ltd.16:45 – 17:05
Translation Medicine from CMC perspectives, from Preclinical to Commercial
David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)17:05 – 17:30
Panel Discussion
Moderator:
Hsing-Pang Hsieh, Director, National Health Research Institutes, Institute of Biotechnology and Pharmaceutical Research (IBPR)
Panelists:
09:00 – 10:30
Session 11 – AI for Pharma
With the explosive update of generative artificial intelligence (AI) tools such as ChatGPT across
multiple business domains, AI is one topic you can't afford to ignore. Here we'll explore the
transformative role of AI in the pharmaceutical industry, with a spotlight on its uptake in Asia.
We'll highlight AI's impact on drug discovery and development, showcasing how it can
successfully identify drug candidates, optimize clinical trial designs, and predict drug
interactions. Case studies will demonstrate successful AI integration in the pharmaceutical
industry, and how it's currently driving both innovation and efficiency. Attendees will gain
insights into leveraging AI tools to streamline development pipelines and enhance therapeutic
outcomes. AI is reshaping the pharmaceutical landscape in Asia; be sure to join us to find out
how.
multiple business domains, AI is one topic you can't afford to ignore. Here we'll explore the
transformative role of AI in the pharmaceutical industry, with a spotlight on its uptake in Asia.
We'll highlight AI's impact on drug discovery and development, showcasing how it can
successfully identify drug candidates, optimize clinical trial designs, and predict drug
interactions. Case studies will demonstrate successful AI integration in the pharmaceutical
industry, and how it's currently driving both innovation and efficiency. Attendees will gain
insights into leveraging AI tools to streamline development pipelines and enhance therapeutic
outcomes. AI is reshaping the pharmaceutical landscape in Asia; be sure to join us to find out
how.
09:00 – 09:05
09:05 – 09:20
Improving AI Analytical and Predictive Power in Drug Discovery Through Deep Learning Methodologies and Industry Collaboration
Tom Diethe, Head of The Centre for Artificial Intelligence, AstraZeneca, Cambridge UK09:20 – 09:35
Unlocking the Potential of AI for High-Throughput Immunotherapy Drug Discovery Through RNA Splicing
Martin Akerman, Co-Founder & CTO, Envisagenics09:35 – 09:45
Enhancing Drug Discovery with Nuclear Magnetic Resonance & Artificial Intelligence
09:45 – 09:55
Integrating Artificial Intelligence in the Design and Discovery of Novel Protein Degraders
Shu-Jen Chen, Chief Scientific Officer, AnHorn Medicines Co., Ltd.
09:55 – 10:10
Enable Smart, Data-driven Decisions Through AI in Clinical Development Programs
NaHyun Kim, Ph.D., Solution Sales Specialist, Medidata AI, Dassault Systèmes, Medidata
10:10 – 10:30
Panel Discussion
10:45 – 12:15
Session 12– Advances in Genetics and Precision Medicine in Human Diseases
Precision medicine is a discipline that continues to evolve. In this session we'll examine the
latest advancements and applications in this field from a distinguished panel of experts within
both precision medicine and precision health domains. We'll discover how genomic profiling and
personalized treatment strategies are revolutionizing breast cancer care, making a real
difference to patient outcomes. Additionally, we'll highlight breakthroughs in precision
respiratory medicine, such as individualized plans for asthma and chronic obstructive pulmonary
disease (COPD), leveraging genetic and biomarker data. Attendees will gain insights into the
latest research, clinical practices, and future directions in precision medicine and in the wider-
scoped field of precision health. Please join us to learn how precision medicine is transforming
healthcare by providing more personalized and effective treatments.
latest advancements and applications in this field from a distinguished panel of experts within
both precision medicine and precision health domains. We'll discover how genomic profiling and
personalized treatment strategies are revolutionizing breast cancer care, making a real
difference to patient outcomes. Additionally, we'll highlight breakthroughs in precision
respiratory medicine, such as individualized plans for asthma and chronic obstructive pulmonary
disease (COPD), leveraging genetic and biomarker data. Attendees will gain insights into the
latest research, clinical practices, and future directions in precision medicine and in the wider-
scoped field of precision health. Please join us to learn how precision medicine is transforming
healthcare by providing more personalized and effective treatments.
10:45 – 10:50
10:50 – 11:10
Development of Peptide-Based PPI Inhibitor Targeting the BIG3-PHB2 cancer specific complex for Breast Cancer
Toyomasa Katagiri, Director, National Institutes of Biomedical Innovation, Health and Nutrition
11:10 – 11:30
Precision Medicine in Oncology – Today and the Future
John Jiang, Senior Director, Medical & Scientific Affairs, Illumina
11:30 – 11:50
Development of Precision Respiratory Medicine for chronic inflammation and infection
11:50 – 12:15
12:25 – 13:55
Session 13 – Shaping the Future of Digital Health
As more and more elements of healthcare are encompassed into the ever-growing domain of
digital health, join us over lunch as we delve into the latest trends and business strategies in this
field. We'll examine key trends such as telemedicine, wearable health tech, AI-driven
diagnostics, and personalized health apps. In breaking down digital health's transformative
impact on healthcare delivery, this session will also showcase successful global business
strategies and the companies that are navigating the digital health landscape to drive innovation
and market growth. Our lineup of local and international digital health experts will offer their
insights on how to bridge and expand the cross-disciplinary digital health community.
digital health, join us over lunch as we delve into the latest trends and business strategies in this
field. We'll examine key trends such as telemedicine, wearable health tech, AI-driven
diagnostics, and personalized health apps. In breaking down digital health's transformative
impact on healthcare delivery, this session will also showcase successful global business
strategies and the companies that are navigating the digital health landscape to drive innovation
and market growth. Our lineup of local and international digital health experts will offer their
insights on how to bridge and expand the cross-disciplinary digital health community.
12:25 - 12:35
Opening Remarks
- Representative from MOEA, Taiwan
- Eric Y. Chuang, Vice President, General Director, Biomedical Technology and Device Research Laboratories, ITRI
12:35 - 13:15
Digital Health Trends and Global Business Strategies
13:15 - 13:55
Panel Discussion:
Bridging the Gap – Expand the Cross-Disciplinary Digital Health Community
Moderator:
Panelists:
- Nipun Jain, Head of Innovation Hubs & Partnerships for International Region,AstraZeneca Plc
- Tony Lee, Head of Sales, Google Cloud
- Kai-Cheng Hsu, Chief Medical Officer, Chief Medical Officer, Biomedical Technology and Device Research Laboratories, ITRI
- Peter Kurz, Chief Strategy Officer, Quantum International Corp. (QIC)
- Jing-Wei Lee, Superintendent, National Cheng Kung University Hospital (NCKUH)